Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salbutamol dry-powder inhalation - Teva Pharmaceutical Industries

Drug Profile

Salbutamol dry-powder inhalation - Teva Pharmaceutical Industries

Alternative Names: Pr Salamol CFC-Free inhaler - Teva Pharmaceutical Industries; ABS eMDPI; Airmax Salamol; Albuterol DPI - Teva; Albuterol dry-powder inhalation - Teva; Albuterol eMDPI; Albuterol MDPI; Albuterol Spiromax; Albuterol sulfate - Teva; Albuterol-dry-powder-inhalation; ProAir Digihaler; ProAir RespiClick; Salbutamol DPI - Teva

Latest Information Update: 23 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IVAX Corporation
  • Developer Teva Pharmaceutical Industries
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Bronchospasm; Exercise-induced asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Jul 2020 Launched for Bronchospasm (In adolescents, In children, In adults) in USA (Inhalation)
  • 14 Jul 2020 Launched for Bronchospasm (In adolescents, In children, Prevention, In adults) in USA (Inhalation)
  • 17 May 2019 Pharmacokinetics data from a phase III trial in Asthma presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top